Literature DB >> 27367012

Inhibition of Ebola Virus by Anti-Ebola miRNAs in silico.

Zhabiz Golkar1, Roshan Battaria, Donald G Pace, Omar Bagasra.   

Abstract

INTRODUCTION: MicroRNAs (miRNAs) are small, noncoding RNA molecules that regulate transcriptional and posttranscriptional gene regulation of the organisms. miRNA provides immune defense when the body is faced with challenges intracellular agents. miRNA molecules trigger gene silencing in eukaryotic cells. More than 3,000 different human miRNAs (hsa-miRs) have been identified thus far. During ontogenesis, viral or intracellular parasitic infections, miRNAs are differentially expressed to protect the host from intracellular invaders. In a viral infection context, miRNAs have been connected with the interplay between host and pathogen, and occupy a major role in pathogenesis.
METHODOLOGY: An in silico approach was used to analyze the four major Ebola Virus genome sequences including the recently characterized Ebola virus responsible for West African epidemic that has killed over 10,000 people. All totaled, 2,543 mature human miRNA sequences were retrieved through an miR-database, and the identification of mature miRNAs were aligned with full length sequences of the four major Ebola viruses via computational tools.
RESULTS: We identified 32 miRNAs that exhibited significant inhibitory capacity to block more than one EBV strains. miR-607 showed capacity to quell all four major EBVs. Ten putative miRNAs were found to have near perfect identity at seed sequences with numerous targets of Ebola virus that may completely degrade the viral transcripts.
CONCLUSION: We hypothesize that a miRNA-based vaccine can quell Ebola virus infection. Future approaches will focus on validation of these miRNAs in quelling the Ebola virus to further elucidate their biological functions in primate and other animal models.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27367012     DOI: 10.3855/jidc.7127

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  6 in total

Review 1.  Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review.

Authors:  Ming Ming Wen
Journal:  Front Mol Neurosci       Date:  2016-11-22       Impact factor: 5.639

2.  Genome-Wide Search for Competing Endogenous RNAs Responsible for the Effects Induced by Ebola Virus Replication and Transcription Using a trVLP System.

Authors:  Zhong-Yi Wang; Zhen-Dong Guo; Jia-Ming Li; Zong-Zheng Zhao; Ying-Ying Fu; Chun-Mao Zhang; Yi Zhang; Li-Na Liu; Jun Qian; Lin-Na Liu
Journal:  Front Cell Infect Microbiol       Date:  2017-11-21       Impact factor: 5.293

3.  A Rapid Screen for Host-Encoded miRNAs with Inhibitory Effects against Ebola Virus Using a Transcription- and Replication-Competent Virus-Like Particle System.

Authors:  Zhongyi Wang; Jiaming Li; Yingying Fu; Zongzheng Zhao; Chunmao Zhang; Nan Li; Jingjing Li; Hongliang Cheng; Xiaojun Jin; Bing Lu; Zhendong Guo; Jun Qian; Linna Liu
Journal:  Int J Mol Sci       Date:  2018-05-16       Impact factor: 5.923

Review 4.  A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment.

Authors:  James Schuler; Matthew L Hudson; Diane Schwartz; Ram Samudrala
Journal:  Molecules       Date:  2017-10-20       Impact factor: 4.411

Review 5.  Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.

Authors:  Kuldeep Dhama; Kumaragurubaran Karthik; Rekha Khandia; Sandip Chakraborty; Ashok Munjal; Shyma K Latheef; Deepak Kumar; Muthannan Andavar Ramakrishnan; Yashpal Singh Malik; Rajendra Singh; Satya Veer Singh Malik; Raj Kumar Singh; Wanpen Chaicumpa
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

6.  Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study.

Authors:  Dawei Jiang; Xiangfei Yuan; Jianqi Ni; Lan Shen; Min Cai; Liu Xu
Journal:  Can J Gastroenterol Hepatol       Date:  2021-06-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.